Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Strategies to Reduce Addiction Stigma Among Health Professionals

8 novembre 2021 aggiornato da: Johns Hopkins Bloomberg School of Public Health

Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Professionals: A Randomized Experiment

The aim of this study was to evaluate the effects of exposure to stigma reduction message frames communicated by visual campaigns and narrative vignettes among a national sample of health professionals.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This randomized experiment evaluated the impact of exposure to message frames communicating the importance of non-stigmatizing language regarding addiction and the effectiveness of medication treatment for opioid use disorder delivered through a visual campaign alone or through a visual campaign in addition to a narrative vignette from the perspective of one of three messengers (a person with opioid use disorder, a clinician, or a health system leader) on attitudes toward people with opioid use disorder and medications for treating opioid use disorder among a national sample of health professionals.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1842

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Stati Uniti
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21205
        • Johns Hopkins Bloomberg School of Public Health

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • employed as health professional in the United States, including clinicians (e.g., physicians, nurses, physician assistants, pharmacists, and optometrists), technicians and technologists (e.g., laboratory technologist or technician, emergency medical technician, paramedic, licensed practical or licensed vocational nurse, medical records or health information technician, etc.), health aids and assistants (e.g., nursing aide, home health aide, medical assistant, pharmacy aide, phlebotomist, etc.)
  • participant in existing web-based survey panel (IPSOS's KnowledgeNetworks panel and partner opt-in panel)

Exclusion Criteria:

  • not employed in health profession
  • not able to complete experiment and survey in English

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: No exposure control group
This group was not exposed to any message frame.
Sperimentale: Words Matter - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
Comportamentale: Words Matter - Visual Campaign
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
Sperimentale: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
Comportamentale: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
Sperimentale: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
Comportamentale: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
Sperimentale: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
Comportamentale: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
Sperimentale: Medication Treatment Works - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
Comportamentale: Medication Treatment for Opioid Use Disorder Works - Visual Campaign
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
Sperimentale: Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
Comportamentale: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
Sperimentale: Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
Comportamentale: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
Sperimentale: Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
Comportamentale: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rating of willingness to have person with opioid use disorder marry into their family
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder marry into the family. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person with opioid use disorder as a neighbor
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder as a neighbor. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that opioid use disorder is a medical condition
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Opioid use disorder is a chronic medical condition like diabetes mellitus" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that individuals with opioid use disorder are to blame
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Individuals with opioid use disorder only have themselves to blame for their problem" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of support for increasing government spending on opioid use disorder treatment
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of support for increasing government spending on treatment of opioid use disorder with 5 indicating strongly favoring and 1 indicating strongly opposing. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Feeling thermometer measure of warmth toward people with opioid use disorder
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of warmth felt toward people with opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Stigmatizing Language - Addict
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "addict" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - Substance abuse
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "substance abuse" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - dirty
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "'dirty' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - clean
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "'clean' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - addicted baby
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "addicted baby" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - person with substance use disorder
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "person with substance use disorder" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - substance use
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "substance use" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - negative test result
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "negative test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - positive test result
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "positive test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - baby born with neonatal opioid withdrawal syndrome
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "baby born with neonatal opioid withdrawal syndrome" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Willingness to sign pledge committing to using non-stigmatizing language
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Binary (yes/no) measure of whether participant is willing to sign a pledge committing to using non-stigmatizing language related to substance use disorder in clinical settings. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Perception of opioid use disorder treatment effectiveness
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Participant perception of whether there is a treatment for opioid use disorder that is effective for a long period of time (three close-ended response options: yes, there is a treatment; no, there isn't such a treatment; don't know). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication marry into their family
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication to treat opioid use disorder marry into family. Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder marry into the family. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication marry as a neighbor
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication to treat opioid use disorder as a neighbor. Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder as a neighbor. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of strength/weakness of person taking medication
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of strength/weakness of person taking medication to treat opioid use disorder on 5-point Likert scale with 5 indicating strong and 1 indicating weak. This is a semantic differential measure. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that recovery is possible
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Most people with opioid use disorder will, with medication treatment, get well and return to productive lives" on a 5-point Likert scale with 5 indicating strongly disagree and 1 indicating strongly agree. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Feeling thermometer measure of warmth toward people taking medication
Lasso di tempo: Measured immediately post-exposure to message frame intervention
Rating of warmth felt toward people taking medication to treat opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Johns Hopkins Bloomberg School of Public Health

Investigatori

  • Investigatore principale: Alene Kennedy-Hendricks, PhD, Johns Hopkins Bloomberg School of Public Health

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 novembre 2020

Completamento primario (Effettivo)

30 novembre 2020

Completamento dello studio (Effettivo)

30 novembre 2020

Date di iscrizione allo studio

Primo inviato

28 ottobre 2021

Primo inviato che soddisfa i criteri di controllo qualità

8 novembre 2021

Primo Inserito (Effettivo)

19 novembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 novembre 2021

Ultimo verificato

1 novembre 2021

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • IRB14743

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi